- Traders flagged Bristol-Myers Squibb (BMY) as a potential bidder for Sellas Life Sciences ahead of Sellas’s Regal AML readout; BMY has made no bid or official comment.
- Bristol-Myers Squibb (BMY) and BioNTech are developing bispecific antibody cancer therapies; BMY is running Phase 3 trials in solid tumors and advancing late-stage immuno-oncology candidates.
TradingView
Key facts: BMY Flagged as Sellas Bidder; BMY,BioNTech on Bispecifics
- Sources
- TradingView
- Markets
- Stocks
- Active symbols
- NYSE:BMY
- Language
- English (India)
Traders flagged Bristol-Myers Squibb (BMY) as a potential bidder for Sellas Life Sciences ahead of Sellas’s Regal AML readout; BMY has made no bid or official comment.Bristol-Myers